Released Nov 9, 2026, before the open
10-Q filed Nov 9, 2026, 40 days after period end · 0001193125-26-452699
What the release said
Orthofix revised its full-year 2026 guidance, with net sales now expected at $825 million to $830 million, down from $845 million to $855 million, and adjusted EBITDA at $86 million to $88 million, down from $95 million to $98 million.¶1¶2¶3
For the third quarter of 2026, net sales were $207.9 million, up 1.1% on a reported basis, and reported net loss was $(6.1) million, or $(0.15) per share, compared with $(22.8) million, or $(0.57) per share, a year earlier.¶4¶5
Non-GAAP adjusted EBITDA was $26.0 million, or 12.5% of pro forma net sales, in the third quarter of 2026, compared with $24.6 million, or 12.1% of pro forma net sales, in the third quarter of 2025.¶5
Global Spine Fixation 1 net sales increased 1%, Global Limb Reconstruction net sales increased 8% on a reported basis, and Therapeutic Solutions net sales increased 4% compared with the prior year period.¶6¶7¶8
Cash, cash equivalents, and restricted cash totaled $86.9 million at September 30, 2026, compared with $104.4 million at June 30, 2026.¶9
- Q3 2026 reported net sales
- $207.9 million¶4
- Q3 2026 reported net loss
- $(6.1) million¶5
- Q3 2026 non-GAAP adjusted EBITDA
- $26.0 million¶5
- Revised full-year 2026 net sales guidance
- $825 million to $830 million pro forma net sales guidance, compared with prior guidance of $845 million to $855 million¶2
- Revised full-year 2026 adjusted EBITDA guidance
- $86 million to $88 million non-GAAP adjusted EBITDA guidance, compared with prior guidance of $95 million to $98 million¶3
- Cash, cash equivalents and restricted cash
- $86.9 million at September 30, 2026, compared with $104.4 million at June 30, 2026¶9
Same quarter
| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $207.86M | $205.63M | $196.61M | $184.01M |
| Net Income | -$6.07M | -$22.80M | -$27.39M | -$28.86M |
| EPS Diluted | -$0.15 | -$0.57 | -$0.71 | -$0.77 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Orthofix Medical Inc. · CIK 884624 · Engraved from SEC EDGAR